Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CAN008,Temozolomide
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : CANbridge Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The results demonstrate that CAN008 has excellent safety and tolerability in patients with GBM and could potentially improve the quality life and the survival time of the patients.
Brand Name : CAN008
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 26, 2021
Lead Product(s) : CAN008,Temozolomide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : CANbridge Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Hydroxychloroquine Sulphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Recipient : University of Cologne
Deal Size : Not Applicable
Deal Type : Not Applicable
COVID-19: Targeted Treatment Trial Launched in Vienna
Details : ACOVACT is a randomised, controlled, multi-centre, open-label clinical trial sponsored by MedUni Vienna. Within ACOVACT, different treatments for COVID-19 are compared to one another. The trial will evaluate Fas ligand blocker asunercept.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 22, 2020
Lead Product(s) : Hydroxychloroquine Sulphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Recipient : University of Cologne
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Asunercept
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The ASUNCTIS trial is a multi-center, randomized, controlled, open-label phase II trial to assess the efficacy and safety of asunercept in patients with severe COVID-19 disease.
Brand Name : APG101
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 13, 2020
Lead Product(s) : Asunercept
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Asunercept
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Apogenix to Start European Clinical Phase II Trial with Asunercept in COVID-19 Patients
Details : The ASUNCTIS trial will be a multi-center, randomized, controlled, open-label trial to assess the efficacy and safety of asunercept in patients with severe COVID-19 disease.
Brand Name : APG101
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 28, 2020
Lead Product(s) : Asunercept
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?